LIVZON PHARMAC. GRP H YC1 (LP6) - Total Liabilities
Based on the latest financial reports, LIVZON PHARMAC. GRP H YC1 (LP6) has total liabilities worth €8.61 Billion EUR (≈ $10.07 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LP6 shareholders equity momentum to track the company's year-over-year net asset growth rate.
LIVZON PHARMAC. GRP H YC1 - Total Liabilities Trend (2021–2025)
This chart illustrates how LIVZON PHARMAC. GRP H YC1's total liabilities have evolved over time, based on quarterly financial data.
LIVZON PHARMAC. GRP H YC1 Competitors by Total Liabilities
The table below lists competitors of LIVZON PHARMAC. GRP H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wereldhave NV
AS:WHA
|
Netherlands | €1.30 Billion |
|
Yuanta Futures Co Ltd
TWO:6023
|
Taiwan | NT$165.17 Billion |
|
Daktronics Inc
NASDAQ:DAKT
|
USA | $252.64 Million |
|
Vivenio Residencial SOCIMI S.A.
MC:YVIV
|
Spain | €516.27 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
China | CN¥275.13 Million |
|
Univest Corporation Pennsylvania
NASDAQ:UVSP
|
USA | $7.49 Billion |
|
BALTIC CLASSIF.GR LS 001
F:983
|
Germany | €31.75 Million |
|
Reysas Tasimacilik ve Lojistik Ticaret AS
IS:RYSAS
|
Turkey | TL9.11 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down LIVZON PHARMAC. GRP H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LP6 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LIVZON PHARMAC. GRP H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below shows the annual total liabilities of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €8.44 Billion ≈ $9.87 Billion |
-11.64% |
| 2024-12-31 | €9.55 Billion ≈ $11.17 Billion |
-7.08% |
| 2023-12-31 | €10.28 Billion ≈ $12.02 Billion |
+3.49% |
| 2022-12-31 | €9.93 Billion ≈ $11.61 Billion |
+23.21% |
| 2021-12-31 | €8.06 Billion ≈ $9.42 Billion |
-- |
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more